NCT00242931撤回2 期
Pilot Trial of Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Hormone-Refractory Prostate Cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Treatment-related mortality as measured by Kaplan-Meier at 5 years following transplant
研究概览
简要总结
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving fludarabine together with total-body irradiation works in treating patients who are undergoing a donor stem cell transplant for progressive metastatic prostate cancer that has not responded to previous hormone therapy.
详细描述
OBJECTIVES:
- Determine the treatment-related mortality in patients with hormone-refractory, progressive metastatic prostate cancer treated with nonmyeloablative conditioning comprising fludarabine and total-body irradiation followed by allogeneic hematopoietic stem cell transplantation.
OUTLINE:
- Nonmyeloablative conditioning regimen: Patients receive fludarabine IV on days -4 to -2 and total-body irradiation (TBI) on day 0.
- Allogeneic hematopoietic stem cell transplantation (AHSCT): After TBI, patients undergo AHSCT on day 0.
- Immunosuppression: Patients receive oral cyclosporine twice daily on days -3 to 56 followed by a taper until day 81. Patients also receive oral mycophenolate mofetil twice daily on days 0-27 (if patient has a related donor) OR three times daily on days 0-29 and then twice daily on days 30-149 followed by additional tapering until day 180 (if patient has an unrelated donor).
PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •4.1.1 Males aged 18-
- •4.1.2 Pathologically proven adenocarcinoma of the prostate with metastases and progressive disease (new metastatic lesions or increase in cancer-related pain or a rising PSA defined by consensus criteria. (A rising PSA will be defined as 2 measurements higher than an initial value. The second of the 3 measurements must be at least 7 days after the first).
- •4.1.3 Progressive disease despite hormonal management (including antiandrogen withdrawal, 6 weeks for bicalutamide, 4 weeks for flutamide or nilutamide)
- •4.1.4 PSA > 5 ng/mL
- •4.1.5 Serum testosterone level < 50 ng/mL
- •4.1.6 Prior treatment with a docetaxel-based regimen.
- •4.1.7 Performance status: Karnofsky Performance Scale (KPS) 70-100%. (Appendix III).
- •4.1.8 Signed informed patient consent.
- •4.2 Patient Exclusion criteria:
- •4.2.1 Expected survival less than 6 months
- •4.2.2 Active central nervous system involvement or spinal instability
- •4.2.3 Organ dysfunction:
- •4.2.3.1 Cardiac: Ejection fraction <35% or symptomatic congestive heart failure.
- •4.2.3.2 Pulmonary: DLCO <40% of predicted or either TLC or FEV1 < 30% predicted.
- •4.2.3.3 Liver dysfunction: serum total bilirubin >2x upper limit of normal (ULN) or either ALT or AST >4x ULN
- •4.2.3.4 Renal dysfunction: creatinine clearance < 50 ml/min
- •4.2.4 HIV seropositivity
- •4.2 Related Donor Inclusion criteria:
- •4.3.1 Age 18-75
- •4.3.2 Related to the patient and genotypically or phenotypically HLA-identical. (Appendix IV)
- •4.3.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and apheresis collection. Bone marrow donors are not eligible.
- •4.3 Unrelated Donor Inclusion criteria:
- •4.4.1 Age 18-
- •4.4.2 Unrelated donors who are prospectively:
- •4.4.2.1 Matched for HLA-DRB1 and -DQB1 alleles by high resolution typing AND 4.4.2.2 Matched for all serologically recognized HLA-A or -B or -C antigens and at least five of six HLA-A or -B or -C alleles as defined by Appendix IV.
- •4.4.3 Able to give consent to peripheral blood stem cell mobilization with G-CSF and apheresis collection. Bone marrow unrelated donors are not eligible.
- •4.4 Related and Unrelated Donor Exclusion criteria:
- •4.5.1 Identical twin.
- •4.5.2 Any contraindication to the administration of G-CSF for mobilization.
- •4.5.3 Serious medical or psychological illness.
- •4.5.4 Prior malignancy within the preceding five years, with the exception of non-melanoma skin cancers.
- •4.5.5 HIV seropositivity.
- •4.5.6 The donor is pregnant, has a positive serum ßhCG or is lactating.
排除标准
- 未提供
结局指标
主要结局
Treatment-related mortality as measured by Kaplan-Meier at 5 years following transplant
次要结局
- Safety by CTCAE v 3.0 at 100 days following transplant
- Response rate by RECIST criteria at 5 years following transplant
- Time to progression by Kaplan-Meier at 5 years following transplant
- Overall survival by Kaplan-Meier at 5 years following transplant
- Response as measured by a 50% reduction in the prostate-specific antigen at 5 years following transplant
研究者
相似试验
已完成
2 期
Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal CancerCervical CancerVaginal CancerNCT00005941Fred Hutchinson Cancer Center
终止
2 期
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By SurgeryKidney CancerNCT00243009OHSU Knight Cancer Institute1
已完成
2 期
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous LeukemiaLeukemiaNCT00110058Fred Hutchinson Cancer Center40
已完成
1 期
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic CancerChronic Myeloproliferative DisordersGraft Versus Host DiseaseMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative DiseasesLymphomaLeukemiaNCT00255710Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins60
已完成
1 期
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerChronic Myeloproliferative DisordersMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsPrecancerous ConditionLymphomaLeukemiaNCT00245037OHSU Knight Cancer Institute147